# EDGAR Filing Document

**Accession Number:** 0001757499
**File Stem:** 0001493152-26-006667
**Filing Date:** 2026-2
**Character Count:** 2194
**Document Hash:** fe02cbfa9dcf572b02a670e002a2b8a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-006667.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0001493152-26-006667

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shuttle Pharmaceuticals Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001757499
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 401 PROFESSIONAL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879
- **BUSINESS PHONE:** (240) 403-4212

**MAIL ADDRESS:**
- **STREET 1:** 401 PROFESSIONAL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879

Shuttle Pharmaceuticals Holdings, Inc.

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

February 13, 2026

*<u>VIA EDGAR</u>*

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

RE: Shuttle Pharmaceuticals Holdings, Inc. (CIK: 0001757499) <br> <u>Registration Statement No. 333-293363 on Form S-1 (the "Registration Statement")</u>

Ladies and Gentlemen:

Shuttle Pharmaceuticals Holdings, Inc. (the "<u>Registrant</u>") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it may become effective on February 17, 2026, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Aaron Schleicher, Esq. of Sullivan & Worcester LLP at (212) 660-3034 and that such effectiveness also be confirmed in writing.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| Shuttle Pharmaceuticals Holdings, Inc. | Shuttle Pharmaceuticals Holdings, Inc. |
| By: | */s/ Christopher Cooper* |
| Name: | Christopher Cooper |
| Title: | Interim Chief Executive Officer |

---